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Increased B cell-activating factor (BAFF) level in the 
sputum of children with asthma
Purpose: B cell-activating factor (BAFF) is a tumor-necrosis factor 
(TNF) superfamily member best known for its role in the survival and 
maturation of B cells. BAFF activity is observed in naïve cells as well 
as in effector/memory T cells. We aimed to explore whether BAFF 
in sputum is expressed at elevated levels in asthmatic airways and 
associated with eosinophilic inflammation, pulmonary function, and 
bronchial hyperresponsiveness in children.
Methods: One hundred and fifty-four asthmatic children and 98 
healthy children were enrolled in the study. Sputum supernatants were 
collected and sputum BAFF and eosinophil cationic protein (ECP) 
levels were measured. We performed pulmonary function tests and 
methacholine challenge tests, while measuring total eosinophil count, 
total serum IgE, and serum ECP in all subjects.
Results: Asthmatic children had significantly higher levels of BAFF in 
induced sputum [26.50 (10.50-100.27) pg/mL] compared to healthy 
children [18.32 (7.68-44.63) pg/mL; P=0.011]. Sputum BAFF positively 
correlated with sputum eosinophils (γ=0.406, P<0.001) and sputum 
ECP (γ=0.789, P<0.001). Significant negative correlations were 
found between sputum BAFF and FEV1 (γ=-0.291, P<0.001) or post-
bronchodilator FEV1 (γ=-0.334, P<0.001), whereas nonsignificant 
correlations were found between sputum BAFF and bronchial 
hyperresponsiveness, serum eosinophil count, and serum ECP. 
Conclusion: These findings suggest that BAFF may play a role in 
childhood asthma, and BAFF levels in sputum could be a supportive 
marker that represents airway inflammation, especially eosinophilic 
inflammation.
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Introduction
Asthma is a chronic inflammatory disease in the airway that 
causes reversible or irreversible contraction of the airway and causes 
sudden dyspnea through a complex inflammatory reaction that 
includes allergic reactions. Asthma occurs from the interaction 
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-
nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
796     HM Jee, et al. • Increased BAFF level in the sputum of children with asthma
of genetic factors and environmental factors. One of the most 
important pathophysiologies in asthma, however, is an allergic 
inflammation that is caused by persistent exposure to allergens1). 
When an allergen is recognized by Th2 cell, cytokines such as 
IL-4 and IL-5 that promote the maturation and differentiation of 
the B cell are secreted due to the activation of the Th2 cell. These 
cytokines induce the B cell to be differentiated into a plasma cell 
and to produce the immunoglobulin E (IgE) antibody that has an 
important role in allergic inflammation2).
B cell-activating factor (BAFF), also known as BLys, TALL-1, 
zTNF4, or THANK, is part of the tumor necrosis factor family 
and is known as having an important role in differentiating the B 
cell and maintaining the shape of a mature B cell. In particular, 
BAFF is an important factor of the proliferation, differentiation, 
and survival of an undifferentiated B cell in the spleen3-5). A 
previous study reported that the B cell in the follicular zone and 
the marginal zone was not found in a BAFF-deficient mouse, 
which indicates that BAFF is an essential factor of the homeostatic 
expression, differentiation, and proliferation of the B cell6, 7). The 
high concentration of BAFF was clinically measured in patients 
with autoimmune diseases that show the over-differentiation of 
the B cell such as in rheumatic arthritis, autoimmune diabetes, 
Sjögren’s syndrome, and multiple sclerosis7, 8). The activity of BAFF 
was also observed in the T cell9), and it was further found that 
BAFF affects the regulation of the interaction between an antigen-
presenting cell and the T cell4). Based on the results of a previous 
study, several studies have been recently conducted to identify the 
detailed mechanism in which BAFF has a certain role in the allergic 
reaction that is a multiple immune response of the T cell and the B 
cell10-12). They reported that the BAFF concentration in the serum 
in patients with asthma was higher than in the normal group10), 
but that there was no difference between the patients with atopic 
dermatitis and the normal group11). Therefore, the exact role of 
BAFF in allergic diseases is not yet known. 
In this study, the level of BAFF in the sputum of patients with 
asthma, a typical allergic disease, was measured to investigate its 
clinical significance and correlation. In addition, its associations 
with conventional asthma-related factors and pulmonary function 
variables were investigated. 
Materials and methods
1. Subject
Two hundred and fifty-two children who visited Severance 
children’s hospital were investigated. Of the 252 children, 154 
subjects who were diagnosed with asthma were assigned to the 
patient group, and 98 subjects were assigned to the control group. 
According to the guidelines of the American Thoracic Society, 
asthma was defined as the cases of the pediatric patients who visited 
the hospital within the past 12 months due to cough without cold, 
wheezing, and dyspnea, in whom bronchial hyperresponsiveness 
(PC20<16 mg/mL) was observed in a methacholine bronchial 
challenge test or whose forced expiratory volume in one second 
(FEV1) after inhalation of the β2 agonist increased by 12% from the 
pre-inhalation state, in which case the reversibility of the condition 
was confirmed13, 14). Of the patients with asthma, 76 received 
treatment for asthma, including the inhalation of steroids in the 
past four weeks, whereas 78 did not receive any treatment. The 
control group was defined as those with no cases of wheezing, no 
medical history of other chronic diseases, and no medical history 
of infection within the past two weeks, and, among the subjects 
who visited the hospital for a health examination or a vaccination, 
those who did not show bronchial hyperresponsiveness in the 
methacholine challenge test. This study was approved by the 
Institutional Review Board of Severance Hospital and informed 
consent was obtained from the children’s parents.
2. Method
1) Collection and treatment of sputum
The induction and collection of sputum was performed 
according to the protocol that Yoshikawa et al. reported15). After all 
the subjects were asked to wash their mouth with tap water, sputum 
was collected from them by inducing coughing at three-minute 
intervals after their inhalation of 3 mL of 3% saline solution for 10-
20 minutes using an ultrasonic nebulizer (NE-U12; Omron Co., 
Tokyo, Japan). The pulmonary function was measured each time 
after the sputum induction. If FEV1 decreased to below 70%, the 
induction was halted. The sputum induction was resumed after 
FEV1 returned to its baseline value. The collected sputum was 
immediately treated within 2 hours or stored at 4℃ to minimize 
cell destruction. Subsequently, after the sputum was diluted five 
times with PBS that included 10 mmol/L of dithiothreitol (WAKO 
Pure Chemical Industries, Ltd., Osaka, Japan), it was stirred with 
a vortex mixer at room temperature for 20 minutes and then 
centrifuged at 2,000 rpm once the mucous component had melted. 
The suspension was stored at -70℃, and the precipitate was smeared 
on a slide using cytospin (Cytospin3: Shandon, Tokyo, Japan), 
followed by May-Grünwald-Giemsa staining. The percentages (%) 
of the neutrophils, lymphocytes, macrophages, and eosinophils 
were calculated after the slides that had 400 or more non-squamous 
cells were chosen. The numbers of the cells were counted using a 
hemocytometer (BLAUBRAND® counting chambers, Wertheim, 
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Germany). The survival rates of the cells were measured after the 
cells were stained with a 0.4% trypan blue solution, and cells with 
survival rates lower than 70% were excluded from the results.  
2) Pulmonary function test and methacholine challenge test 
A pulmonary function test was performed using spirometry 
(Vmax encore, VIASYS Healthcare, Inc., Hoechberg, Germany) 
according to the standards of the American Thoracic Society14). 
In the three trials that were performed at each time point, the 
maximum FEV1 was selected. A methacholine challenge test was 
performed after it was confirmed that the FEV1 was more than 
70% of the normal estimated value in the pulmonary function 
test16). In the methacholine challenge test, after methacholine was 
dissolved in a saline solution buffer and diluted to 0.075, 0.15, 
0.31, 0.62, 1.25, 2.5, 5, 10, 25, and 50 mg/mL concentrations, the 
test was performed using a Rosenthal-French dosimeter (Ferraris, 
Hertford, England) via inhalation of methacholine with an 
aerosol through a Devilbiss 646 nebulizer for 0.6 seconds. Sixty 
to 90 seconds after the inhalation of increasing concentrations of 
methacholine at t5-minute intervals, FEV1 was measured. This 
process was repeated with increasing methacholine concentrations 
until the FEV1 decreased by more than 20% from the baseline 
value. The methacholine concentration at the point at which FEV1 
decreased by 20% (PC20) in the dose-response curve was calculated. 
Bronchial hyperresponsiveness was defined as that in a case in 
which the PC20 was 16 mg/mL or less. The administration of an 
anti-inflammatory drug and a bronchodilator was halted 24 hours 
before the test. 
3) Measurement of the number of eosinophils, total IgE, and 
the eosinophil cationic protein (ECP) in the serum, ECP, 
and BAFF in the sputum
The number of eosinophils in the blood was counted using 
the NE-8000 system (Sysmax, Kobe, Japan) after the collection 
of peripheral blood. The total IgE in the serum and the total 
blood ECP and sputum ECP were measured using the CAP 
radioallergosorbent technique (UniCAP; Pharmacia and Upjohn, 
Uppsala, Sweden). The sputum BAFF was measured using 
commercial ELISA kits (R&D Systems, Inc., Minneapolis, MN, 
USA). The minimum concentration of 16 pg/mL was measured. 
The concentration of sputum BAFF was measured using a 
microplate reader (VERSA max) twice at OD450 nm, and the 
mean values were analyzed. 
3. Statistics
The mean±SD was used when the variables (the number of 
eosinophils in the blood, the total IgE in the serum, the ECP, the 
sputum ECP, BAFF, and PC20) were normal, and the median 
(interquartile range) was used when the variables were abnormal. 
The student’s t-test or the Mann-Whitney test was used to compare 
the asthma group with the control group. The correlations of 
the sputum BAFF’s concentration with the pulmonary function 
variables and PC20 were calculated using Pearson’s correlation test. 
The abnormal variables were converted into common logarithms 
and analyzed. They were considered statically significant when their 
P value<0.05. SPSS version 13.0 (SPSS, Inc., Chicago, IL) was used 
for all the statistical analyses. 
Results
1. Characteristics of the pediatric subjects
The study subjects were a total of 252 children aged 8.76±2.43 
years, of whom 159 (63.1%) were male and 93 (36.9%) were 
female. 154 of the subjects belonged to the asthma group, and 98, 
to the normal control group. The mean values of the numbers of 
eosinophils in the sputum and eosinophils in the blood, as well as 
of the total IgE and ECP, were more statically significant in the 
asthma group than in the control group (P<0.001, Table 1).
2. Comparison of the two groups’ BAFF concentrations in 
the sputum  
The concentration of the sputum BAFF was significantly 
higher in the pediatric patients with asthma than in the normal 
group [26.50 (10.50-100.27) pg/mL vs. 18.32 (7.68-44.63) pg/
mL, P=0.011, Fig. 1A]. When the pediatric patients with asthma 
were divided into two groups, the pre-treatment group who were 
subjected to steroid inhalation (n=74) and the post-treatment group 
Table 1. Demographics of Subjects
Asthma
(N=154)
Control
(N=98)
Sex (male/female)
Age (yr)
Sputum eosinophil count (%)
Serum eosinophil count (log /μL)
Total serum IgE (log IU/mL)
Sputum ECP (μg/L)
Serum ECP (log μg/L)
FEV1 (%predicted)
Post-bronchodilator FEV1 (%predicted)
FEV1/FVC (%)
FEF25-75 (%predicted)
         104/50
8.42±2.35
17.98±23.53*
2.41±0.40*
2.24±0.72†
38.85±32.36*
1.37±0.44
86.62±16.64*
94.01±17.82†
87.33±11.94*
80.94±32.43*
        55/43
9.29±2.46
0.57±1.18
2.62±0.42
2.63±0.44
23.02±23.02
1.32±0.43
93.67±17.54
98.97±13.84
93.52±6.61
105.34±23.78
Results are indicated as means±SD.
Abbreviation: ECP, eosinophil cationic protein
*P<0.001 between asthma and control.
†P<0.05 between asthma and control.
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(n=76), it was found that the concentrations of the sputum BAFF 
in the pre-treatment group were higher than those in the post-
treatment or normal group [33.60 (9.79-113.56) pg/mL vs. 23.86 
(10.76-78.48) pg/mL vs. 18.32 (7.68-44.63) pg/mL, P=0.003 and 
P=0.036, respectively]. The difference in the concentrations of the 
sputum BAFF of the pre- treatment group and the post-treatment 
group (P=0.356) was not statistically significant, though (Fig. 1B).
3. Correlation of the BAFF concentration in the sputum 
with ECP and the number of eosinophils in the sputum
The sputum BAFF showed significantly positive correlations 
with the sputum ECP (γ=0.406, P<0.001) and the number of 
eosinophils (γ=0.789, P<0.001), respectively (Fig. 2A, B). It showed 
no statistically significant correlation, however, with the total 
number of eosinophils, ECP, and IgE concentration in the blood.  
4. Correlation of the BAFF concentration in the sputum 
with the values from the pulmonary function test  
The concentration of the sputum BAFF showed significantly 
negative correlations with FEV1 (γ=-0.291, P<0.001), FEV1 (γ
=-0.334, P<0.001), and FEF25-75 (γ=-0.257, P<0.001) after the 
inhalation of a bronchodilator in the pulmonary function test (Fig. 
3A, B, and C). No statistically significant correlation with PC20 and 
FEV1/FVC was found, though. 
Discussion
In this study, it was shown that sputum BAFF is involved in the 
pathophysiology of asthma after it was seen that the concentration 
of the sputum BAFF was higher in the asthma group than in the 
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Fig. 2. Sputum B cell-activating factor (BAFF) showed definitely positive 
correlations with sputum ECP (A) and sputum eosinophils (B).
Fig. 1. (A) Sputum B cell-activating factor (BAFF) levels in asthma and 
control groups. Asthmatic children had significantly higher levels of 
BAFF in induced sputum [26.5 (10.5-100.3) pg/mL] compared to healthy 
children [18.3 (7.7-44.6) pg/mL; P=0.011]. (B) Sputum B cell-activating 
factor (BAFF) levels in asthma with/without treatment and control 
groups. BAFF levels of asthmatic group before treatment were higher 
than the levels after treatment in the control group [33.60 (9.79-113.56) 
pg/mL vs. 23.86 (10.76-78.48) pg/mL vs. 18.32 (7.68-44.63) pg/mL, 
P=0.003, P=0.036, respectively).
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normal group and that the concentration of the sputum BAFF had 
no positive correlation with allergic inflammation markers such as 
the number of eosinophils and ECP. 
BAFF has been known as a substance involved in the maturation 
and differentiation of the B cell. It was recently reported as also 
being involved in the immune response of the T cell. BAFF’s role 
with respect to the T cell seems to apply not only to a naïve T cell 
but also to a differentiated T cell4). Therefore, besides BAFF’s role 
with respect to the B cell immune disease or the autoimmune 
disease that were revealed previously, it is also expected to play a 
certain role in diseases related to the T cell. In addition, as BAFF’s 
involvement in IgE class switching in the B cell regulation process 
has yet to be identified, it is presumed that BAFF has an impact 
on the mechanism of allergy outbreak. In recent studies, Kang et 
al10) found that the concentration of the serum BAFF in pediatric 
patients with asthma increased, and that such increase is associated 
with the severity of the asthma. Thus, they suggested that BAFF 
should be used as a marker of the severity of asthma. Moon et al12) 
also reported that the symptoms of asthma disappeared when the 
concentration of the serum BAFF decreased. There have been 
reports, however, that BAFF is irrelevant to allergic diseases11). One 
study reported that allergic airway inflammation was suppressed 
in an asthmatic mouse model with high BAFF expression, based 
on which the study proposed that BAFF should not be a causative 
substance or a signaling substance but an outcome substance of 
inflammatory reactions. That is, BAFF should be a substance that 
induces the inhibitory mechanism of allergic inflammation17). 
Although recent studies have reported that the serum BAFF 
is associated with asthma, no study has presented the exact 
mechanism involved. Furthermore, most study results analyzed 
serum BAFF without determining the association of asthma with 
sputum BAFF. 
Asthma is a disease in which reversible airway obstruction and 
airway remodeling occur due to the long-term persistent allergic 
inflammation of the airway. Not only lymphocytes such as B cells 
and T cells, but also various types of inflammatory cells that exist in 
the airway such as airway epithelial cells, eosinophils, and mast cells, 
are involved in the airway inflammation18). Accordingly, induced 
sputum has been used well to measure the degree of inflammation 
both in asthma and other chronic airway inflammatory diseases. 
In addition, as the measurement of the number of eosinophils in 
the sputum helps in the measurement of the change and severity 
of diseases, the measurement of the number of eosinophils using 
induced sputum is being used widely as a non-invasive method 
of monitoring asthma conditions19). In this study, the BAFF 
concentration in induced sputum was measured to investigate its 
association with asthma compared with that of serum BAFF. The 
measurement showed significant results. 
Eosinophil plays an important role in allergic airway inflam-
mation, and ECP, a major product of eosinophil, is used as a 
marker of allergic inflammation. The result of this study, in which 
the sputum BAFF showed strong positive correlations with the 
eosinophils and ECP in the sputum, supports the hypothesis that 
sputum BAFF is associated with asthma and is involved in allergic 
inflammation. Interestingly, the sputum BAFF in the pediatric 
patients with asthma showed no positive correlation with the 
number of eosinophils and the ECP in the serum. Eosinophils in 
the airway directly damage the airway epithelial cells by secreting 
various mediators, including cytokines. Therefore, the eosinophils 
in the airway are thought to be more closely associated with asthma 
than the eosinophils in serum20). This finding likely explains why 
sputum BAFF has a higher correlation with the eosinophils in the 
sputum than in serum. 
The correlation of BAFF with the pulmonary function in the 
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Fig. 3. Correlations between sputum B cell-activating factor (BAFF) and pulmonary function test parameters. Significant negative correlations were 
found between sputum BAFF and FEV1 (A), post-bronchodilator FEV1 (B), a nd FEF25-75 (C).
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asthma group showed a negative correlation with FEV1, but no 
significant correlation with PC20 was found. When the BAFF 
concentrations of the pre-treatment and post-treatment groups 
in the asthma group were compared, however, it was seen that 
the BAFF concentrations before the treatment were significantly 
higher than after the treatment. Based on this result, it seems that 
sputum BAFF is associated with the recent treatment or worsening 
of asthma in patients. In this study, the severity of the asthma in 
the asthma group was not classified for analysis. The degree of the 
symptoms and the association with BAFF will be more clearly 
revealed in the future through the classification of the severity of the 
condition of the asthma group.  
There was no statistical significance between the IgE con-
centration and the BAFF concentration in the sputum. This result 
contradicts the well-known mechanism by which BAFF induces 
an increase in IgE. As in several previous studies that showed the 
correlation of serum BAFF with allergic diseases10, 11), however, the 
concentration of IgE and BAFF did not always show a positive 
correlation in this study. As a result, it is suggested that BAFF 
should not be considered a starting substance of inflammatory 
reaction but an outcome or an inhibitor of inflammatory reaction. 
A further study is required to explore this suggestion. 
In conclusion, this study confirmed that sputum BAFF is 
associated with asthma and has positive correlations with markers 
of allergic airway inflammation such as the number of eosinophils 
and ECP. This study is clinically significant because it showed that 
BAFF is associated with causes of asthma. A further study on the 
mechanism of BAFF in allergic diseases is needed, though. 
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